



Zelda Therapeutics Ltd
ACN 103 782 378
www.zeldatherapeutics.com
Level 45
108 St Georges Terrace,
Perth Western Australia 6000

15 November 2016

SUCCESSFUL \$4M CAPITAL RAISING

HIGHLIGHTS

- **Successful \$4,000,000 capital raising complete**
- **Strong support received from existing and new investors**
- **Company well positioned to progress on multiple fronts**

Zelda Therapeutics Ltd (formerly Gleneagle Gold) (**ASX: ZLD, Zelda** or the **Company**) is pleased to announce that it has successfully raised the maximum allowed under its prospectus offering.

A total of 160,000,000 post-consolidation shares will be issued to new investors at 2.5 cents per share raising the full \$4,000,000.

The funds raised are to continue with pre-clinical R&D activities, fund human clinical trials and expand the management/ advisory team.

The company will now proceed with the formal re-admission process with the Australian Securities Exchange and will provide an update on the indicative listing date in due course.

The company's ASX ticker code has changed from GLN to ZLD.

CONTACTS

Corporate

Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media

Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda's*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols. Zelda will use this information to design a series of Phase 2-ready human clinical trials that have a high probability of success given the existing patient data and experiences it has access to.

In addition, Zelda has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry.